Patent · US Active

Antisense guanidinium peptide nucleic acid (GPNA) oligonucleotides as antitumor agents

US7960360B2 · kind B2 · utility

5Cited by

1References

1Claims

0Family size

Inventors

Jennifer Rubin Grandis · Pittsburgh, US
Sufi Mary Thomas · Springdale Township, US
Danith H. Ly · Pittsburgh, US

Key dates

Filing date	Nov 13, 2007
Grant date	Jun 14, 2011
Priority date	—
Expiry date	Nov 13, 2027

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/51
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

A class of antisense agents having a distributed guanidinium peptide nucleic acids (GPNA) backbone which has excellent uptake into mammalian cells, can bind to the target DNA or RNA in a highly sequence specific manner and can resist nucleases and proteases both outside and inside the cell(s) of interest. In one embodiment, either systemic or intratumoral administration of antisense Epidermal Growth Factor Receptor (“EGFR”) GPNA oligonucleotides is believed to downmodulate EGFR levels, thus in turn to reduce head and neck squamous cell carcinoma tumor growth, which has been confirmed to date both in vitro and in vivo.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.